New combo therapy aims to shrink rectal tumors before surgery
NCT ID NCT06770270
Summary
This study is testing whether adding a new immunotherapy drug called pucotenlimab to the standard pre-surgery treatment (chemotherapy and radiation) works better for people with locally advanced rectal cancer. The goal is to see if this combination helps more patients achieve a complete response, meaning no detectable cancer cells remain, before they undergo surgery. Researchers will enroll 68 adults to assess the safety and effectiveness of this approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital Of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.